Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis

Journal of Drugs in Dermatology

Volumn 10, Issue 6, 2011, Pages 666-672

  Frankel, Amylynne ^a   Sohn, Andrew ^a   Patel, Rita V ^a   Lebwohl, Mark ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE DERIVATIVE; CERAMIDE HYALURONIC ACID; PIMECROLIMUS; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREAM; DEVICE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOAM; HUMAN; MALE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; SINGLE BLIND PROCEDURE; TREATMENT DURATION;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CERAMIDES; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYALURONIC ACID; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053090100     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol. 2010;125(1):4-13.
2. Cork MJ, Robinson DA, Vasilopoulos Y, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: geneenvironment interactions. J Allergy Clin Immunol. 2006; 118(1):3-21. (Pubitemid 43946484)
3. Taylor B, Wadsworth J, Wadsworth M, Peckham C. Changes in the reported prevalence of childhood eczema since the 1939-45 war. Lancet. 1984;2(8414):1255-1257. (Pubitemid 15217725)
4. Williams HC. Is the prevalence of atopic dermatitis increasing? Clin Exp Dermatol. 1992;17(6):385-391.
5. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121(6): p. 1337-43.
6. Blank IH, Moloney J 3rd, Emslie AG, et al. The diffusion of water across the stratum corneum as a function of its water content. J Invest Dermatol. 1984;82(2):188-194. (Pubitemid 14184262)
7. Di Nardo A, Wertz P, Giannetti A, Seidenari S. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol. 1998;78(1):27-30. (Pubitemid 28103674)
8. Addor FA, Aoki V. Skin barrier in atopic dermatitis. An Bras Dermatol. 2010;85(2): p. 184-94.
9. Sugarman JL, Fluhr JW, Fowler AJ, et al. The objective severity assessment of atopic dermatitis score: an objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. Arch Dermatol. 2003;139(11):1417-1422. (Pubitemid 37433131)
10. Elias PM, Feingold KR. Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol. 2001;137(8):1079-1081. (Pubitemid 32756467)
11. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-446.
12. Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin. 2010;26(3):633-640.
13. Zheng PS, Lavker RM, Lehmann P, Kligman AM. Morphologic investigations on the rebound phenomenon after corticosteroid-induced atrophy in human skin. J Invest Dermatol. 1984;82(4):345-352. (Pubitemid 14131459)
14. Du Vivier A. Tachyphylaxis to topically applied steroids. Arch Dermatol. 1976;112(9):1245-1248.
15. Charman CR, Morris AD, Williams, Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142(5):931-936. (Pubitemid 30304603)
16. Turpeinen M, Lehtokoski-Lehtiniemi E, Leisti S, Salo OP. Percutaneous absorption of hydrocortisone during and after the acute phase of dermatitis in children. Pediatr Dermatol. 1988;5(4): p. 276-279. (Pubitemid 19027867)
17. Boguniewicz M, Leung DY. New concepts in atopic dermatitis. Compr Ther. 1996;22(3):144-151.
18. Leung DY, Boguniewicz M, Howell MD, et al., New insights into atopic dermatitis. J Clin Invest. 2004;113(5):651-657. (Pubitemid 38544154)
19. Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005;330(7490):516 [Epub].
20. Wellington K, Noble S. Pimecrolimus: a review of its use in atopic dermatitis. Am J Clin Dermatol. 2004;5(6):479-495. (Pubitemid 40178773)
21. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs. 2002;62(5):817-840. (Pubitemid 34494024)
22. Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol. 2003;111(5):1153-1168.
23. Mao-Qiang M, Brown BE, Wu-Pong S, et al. Exogenous nonphysiologic vs physiologic lipids. Divergent mechanisms for correction of permeability barrier dysfunction. Arch Dermatol. 1995;131(7):809-816.
24. Anderson PC, Dinulos JG. Atopic dermatitis and alternative management strategies. Curr Opin Pediatr. 2009;21(1):131-138.
25. Grimalt R, Mengeaud V, Cambazard F, Study Investigators' Group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007;214(1):61-67. (Pubitemid 46033003)
26. Cronstein BN, Kimmel SC, Levin RI, et al. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA. 1992;89(21):9991-9995.
27. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002;46(2):228-241. (Pubitemid 34118380)
28. Abramovits W, Perlmutter A. MimyX cream. Skinmed. 2006;5(1):29-30.
29. Madaan A. Epiceram for the treatment of atopic dermatitis. Drugs Today (Barc). 2008;44(10):751-755.
30. Green JS, Andersen K, Wilkin J, Siegfried E. Understanding over-the-counter medications and prescription devices for eczema: potential consequences for consumers. J Am Acad Dermatol.2010;63(6):1094-1098.
31. Hylatopic Emollient Foam [package insert] Onset Dermatologics Available from: http://www.onsettx.com/docs/hylatopic/Hylatopic-PI-2611-pf-Rev-2.pdf.
32. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg, 2003;7(3):185-192. (Pubitemid 36859094)
33. Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007;56(2):211-216. (Pubitemid 46074250)
34. Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol. 2007;57(1):81-83. (Pubitemid 46908856)